China Pharma Holdings, Inc.

Name: China Pharma Holdings, Inc. standardized financial statements, quarterly
Creator: Listed

CPHINYSECIK 1106644HealthcareFiscal year ends Dec 31

Share this page

Link

Story card, 1080 × 1920

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$948.3k, Q2 FY2026

Operating income−$1.4m, Q2 FY2026

Net income−$1.5m, Q2 FY2026

China Pharma Holdings, Inc., income statement, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	period not labelled2024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Revenue	$k	1,803	2,150	1,370	925	1,100	1,134	1,136	1,026	756	1,226	984	948
Cost of revenue	$k	2,037	2,229	1,660	1,940	1,620	1,295	1,272	1,113	816	1,075	698	865
Gross profit	$k	(233)	(79.2)	(290)	(1,015)	(520)	(161)	(136)	(87.0)	(59.7)	151	285	83.6
Research and development	$k	45.8	148	31.5	164	87.6	0.5	29.6	21.0	40.3	190	83.8	19.1
Operating income	$k	(714)	(1,184)	(916)	(1,392)	(1,085)	(1,196)	(759)	(652)	(628)	(1,200)	(1,117)	(1,432)
Interest expense	$k	6.9	9.7	6.9	6.9	6.8	6.8	6.8	6.8	6.8	6.9	9.1	9.3
Income tax	$k	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Net income	$k	(778)	(1,232)	(956)	(1,438)	(1,118)	(1,224)	(786)	(528)	(651)	(1,222)	(1,143)	(1,458)
Diluted EPS	$ per share	(0.29)	not reported	(0.72)	(0.89)	(0.65)	not reported	(0.24)	(0.16)	(0.17)	not reported	(0.04)	(0.04)
Basic EPS	$ per share	(0.29)	not reported	(0.72)	(0.89)	(0.65)	not reported	(0.24)	(0.16)	(0.17)	not reported	(0.04)	(0.04)

Balance sheet

Cash and equivalents$304.9k, Q2 FY2026

Shareholders' equity$36.2m, Q2 FY2026

China Pharma Holdings, Inc., balance sheet, quarterly
Line item	Unit	Q3 FY20232023-09-30	FY20232023-12-31	period not labelled2024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Cash and equivalents	$m	1.4	1.4	not reported	not reported	0.7	0.6	0.4	0.6	0.3	0.3	0.2	0.3
Current assets	$m	5.8	6.0	not reported	4.0	3.7	3.3	2.9	2.7	2.3	2.3	2.0	2.0
Total assets	$m	15.4	16.5	not reported	14.3	13.5	14.9	14.2	13.8	15.8	31.0	45.1	44.7
Current liabilities	$m	7.1	6.8	not reported	4.7	4.8	5.0	5.1	5.3	6.6	7.4	7.3	7.7
Total liabilities	$m	9.2	9.0	not reported	6.9	6.9	7.1	7.2	7.3	7.5	8.3	8.1	8.5
Long-term debt	$m	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Short-term borrowings	$m	not reported	1.1	not reported	not reported	not reported	1.1	1.2	1.4	1.4	1.4	1.5	1.6
Shareholders' equity	$m	6.1	7.5	8.3	7.4	6.5	7.7	7.0	6.5	8.3	22.7	37.0	36.2

Cash flow

Operating cash flow−$32.8k, Q2 FY2026

Capital expenditure$454, Q4 FY2025

China Pharma Holdings, Inc., cash flow, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	period not labelled2024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Operating cash flow	$k	1,007	(22.3)	(585)	(72.7)	(47.0)	299	(73.7)	274	(204)	152	(55.3)	(32.8)
Capital expenditure	$k	not reported	not reported	not reported	not reported	(9.2)	19.5	58.3	(0.1)	0.6	0.5	not reported	not reported

Diluted shares (weighted)40.52m, Q2 FY2026

China Pharma Holdings, Inc., shares, quarterly
Line item	Unit	Q1 FY20132013-03-31	Q2 FY20132013-06-30	Q1 FY20152015-03-31	Q2 FY20152015-06-30	Q3 FY20152015-09-30	Q1 FY20162016-03-31	Q2 FY20162016-06-30	Q3 FY20162016-09-30	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Diluted shares (weighted)	m shares	43.6	43.6	43.6	43.6	43.6	43.6	43.6	43.6	3.3	3.2	25.6	40.5

Shares outstanding: 43.02m at Aug 11, 2026, from the cover of the 10-Q filed Aug 14, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:33 ET. Listed shows no prices and gives no investment advice.